Portfolio Companies
CT Atlantic AG is a spin-off of the University of Zurich, Switzerland and the Ludwig Institute of Cancer Research (LICR, Zurich, Switzerland and New York, USA). CT Atlantic’s principle focus is the application of human-derived antibodies as anti-cancer therapeutics. The company’s lead programs target CT antigens such as NY-ESO-1 and MAGEA3. CT Atlantic was founded by Prof. Alexander Knuth, Director of the Department of Clinical Oncology at the University of Zurich. The company is based in Schlieren, Zurich, Switzerland.
Medovent is a medical device company focusing on the development and manufacturing of chitin and chitosan based polymers. The company currently applies its technology in urological stents, surgical sutures, nerve guides and catheter coatings. Medovent was founded by Dr. Thomas Freier (CEO) and Dr. Rivelino Montenegro (CSO) and is based in Mainz, Germany.
Medoderm GmbH is a Medovent GmbH affiliated company focused on developing chitosan-based wound healing products. MedoDerm is based in Mainz, Germany.
PAREQ AG is a spin out from the Institute of Surgical Pathology at the University of Zurich, Switzerland and is focused on the identification of novel biomarkers (PAREQmarkers) through analysis of data derived from a large range of diseases and platforms. In a first project, PAREQ has identified a novel biomarker concept consisting of a series of distinct “states,” demonstrated to be correlated with characteristics such as tumor aggressiveness and patient survival times. Dr. Karsten Henco is founding CEO and Dr. Manfred Beleut is a co-founder and CSO. Pareq is based in Düsseldorf and maintains its research operations in Schlieren, Zurich.
PhenoQuest is an emerging biotech company focusing on the development of novel treatment options for affective disorders such as depression and anxiety. Its lead drug candidate is an antibody against a novel anti-depression target. The company was co-founded by Dr. Inge Sillaber (CEO) and Dr. Herbert Stadler (Chairman of the Board). PhenoQuest is based in Martinsried, Munich, Germany.
Qlaym has developed proprietary software solutions of Automated Artificial Intelligence that use unique sets of algorithms to analyze large and complex data collections for informative clusters of content. The technology has found applications in life sciences and non-healthcare industries. Dr. Karsten Henco is founding CEO and Qlaym´s scientific founder Marcel Thürk serves as CSO. Qlaym is based in Göttingen, Germany.
ImmunoQure AG is an emerging biotech company focused on the development of human-derived antibodies for the treatment of inflammation and autoimmune diseases. The scientific founders of ImmunoQure bring multi-disciplinary translational medicine experience to the company enabling the identification and rescuing of autoantibodies against important mediators of human disease. Dr. Edward Stuart is ImmunoQure’s founding CEO. The company is based in Düsseldorf and maintains research operations in Schlieren, Zurich.
ethris GmbH is a spin out from the Ludwig Maximilians University and the Technical University in Munich. ethris GmbH develops, as the first company world-wide, “Transcript Therapies” based on its proprietary enabling SNIM® RNA platform. SNIM® RNA designates stabilized, non-immunogenic messenger RNA, and is a first-in-class biopharmaceutical platform for the previously unfeasible repeated administration of messenger RNA. Because of its precursor function, SNIM® RNA leads to sustained protein production within the body and overcomes short duration effects of recombinant proteins. SNIM® RNA has the potential to make mRNA therapeutics a reality in a broad variety of medical indications, from hereditary or acquired metabolic diseases to regenerative medicine.
Magnetovax®, ethris’ second proprietary technology, is an enabling platform for immune-stimulating, nucleic acid-based cancer therapeutics. It is used to localize and activate immune stimulation against tumors directly in tumors by magnetic force. Felovectin, a first in class nanomagnetic gene therapeutic agent, has shown very significant therapeutic benefit in a veterinary clinical trial for the treatment of feline fibrosarcoma, the most frequent skin tumor in cats. Magnetovax®-based nanomagnetic compositions can be used in various cancer indications.
